New study tests cheaper h. pylori treatment to beat antibiotic resistance

NCT ID NCT07574983

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two 14-day treatments for H. pylori, a stomach bacteria that can cause ulcers and cancer. About 90 adults will receive either a levofloxacin-based sequential therapy or a bismuth-based quadruple therapy. The goal is to see which treatment works better and has fewer side effects, aiming to find an affordable option for areas with high antibiotic resistance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Levofloxacin-based sequential therapy (dexlansoprazole, amoxicillin, levofloxacin, tinidazole) and bismuth-based quadruple therapy (bismuth subsalicylate, dexlansoprazole)

What this could lead to

If successful, this could identify a more effective and affordable first-line treatment for H. pylori infection, especially in areas with high antibiotic resistance.

What could go wrong

This is a small, early-stage trial with only 90 participants, so results may not apply to everyone. Both treatments can cause side effects like nausea or diarrhea, and antibiotic resistance may still limit effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••